Inspra Label Aims To Limit Hyperkalemia With Monitoring, Contraindications
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacia’s Inspra does not offer benefits over other antihypertensives that would justify its use in patients at high risk for hyperkalemia, FDA concluded in review documents.